ONYX Pharmaceuticals Inactive 10-K2002 FY Annual report

Filed: 25 Mar 03, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	7th grade Avg

New words: Abgenix, Advexin, anecdotal, BRAF, burn, canceled, cancellation, caption, cascade, certify, certifying, commensurate, COMMISSIONWashington, Conference, consolidated, consolidation, constituting, corrective, customer, defective, degree, dividend, Domain, drain, EITF, electronically, encouraging, entity, exit, facilitating, fashion, filer, fraud, furnish, furnished, genome, Guarantor, herewith, Ib, implicit, inserted, insufficient, Investor, issuable, Japanese, learn, lieu, light, loan, macrophage, main, match, melanoma, mice, misleading, moleculesthat, multiplied, mutually, neutralize, nonperformance, older, Organisation, plant, pose, prominent, prospective, randomized, reacquisition, realignment, recommence, redemption, Reform, renal, residual, resumption, Rituxan, RituxanTM, round, Rule, segment, Service, shareholder, shortfall, Similarly, sinking, skill, StockholdersOnyx, summarize, text, Thee, thereof, unamortized, underway, untrue, upcoming, variable, vehicle, virusesthat, VirusTM, vivo, voluntary, web, website

Removed: additionally, array, cisplatin, compliance, context, death, dedicate, deemed, directed, endpoint, enrollment, escalation, experimentation, expired, feasible, foregoing, gemcitabine, granting, hiring, improve, inactivate, initially, initiating, injected, injection, insignificant, intrahepatic, intratumoral, leucovorin, lost, manufacturer, maximum, Medicine, minimize, modify, modifying, modulation, mutation, pivotal, progressed, proven, radiation, refractory, renewed, repayment, rest, retaining, revert, selective, sharing, solid, systematically, tangible, targeted, tolerated, uncertainty, undertaken, washington

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ONYX Pharmaceuticals similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 99.1

CERTIFICATION

Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002 (18 U.S.C. § 1350, as adopted), Hollings C. Renton, Chairman of the Board, President and Chief Executive Officer of Onyx Pharmaceuticals, Inc. (the “Company”), hereby certifies that, to the best of his knowledge:

1.		The Company’s Annual Report on Form 10-K for the period ended December 31, 2002, to which this Certification is attached as Exhibit 99.1 (the “Annual Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

2.		The information contained in the Annual Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Annual Report and results of operations of the Company for the period covered by the Annual Report.


Dated: March 21, 2003


/s/ HOLLINGS C. RENTON Hollings C. Renton Chairman of the Board, President and Chief Executive Officer (Principal Executive and Financial Officer)